Pharmacokinetics and pharmacogenomics study with erlotinib in the treatment of advanced non-small cell lung cancer (NSCLC)

Trial Profile

Pharmacokinetics and pharmacogenomics study with erlotinib in the treatment of advanced non-small cell lung cancer (NSCLC)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2013

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 08 Jun 2013 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan record.
    • 03 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top